incidence of pancreatitis with glp-1 New data links agonists for weight loss higher risk for pancreatitis, GI events GLP-1 Agonist Side Effects: Pancreatitis

These medications, which are used primarily for T2D management, have shown beneficial effects on both cardiac and renal diseases

In the UK, SCoMIS has been announced in 2025, a landmark government-funded and IQVIA-run study will enrol thousands of patients, including those from Scotlands most deprived areas, to assess the impact of obesity treatments in real-world settings

What are clinical trial weight loss results for Saxenda

The March 2026 announcement with Novo Nordisk matters because it shifts Hims & Hers' GLP 1 story from a compounded centric offering to broader access to FDA approved brands, layered on a weight loss membership priced from US$39 to US$149 a month

The global burden of obesity demands accessible and innovative solutions